Mainstay Medical
-
Neuro
Mainstay Medical announces the release of post-marketing data from the ongoing ReActiv8®-C study in patients with chronic low back pain
New real-world findings support the effectiveness and use of ReActiv8® Restorative Neurostimulation™ to treat intractable chronic low back pain November…
Read More » -
Neuro
Mainstay Medical Announces Publication of Three-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™
Data continue to show compelling efficacy and safety, including improvement on all key measures of pain and disability, as compared…
Read More » -
Spine
Mainstay Medical Announces Publication of Two-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™
Data shows compelling efficacy and safety, as well as improvement on all key measures of pain and disability as compared…
Read More » -
Neuro
Mainstay Medical Announces Commercial Launch of ReActiv8® in Australia
March 8, 2021 DUBLIN–(BUSINESS WIRE)–Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced the commercial launch in Australia of…
Read More » -
Financial
Mainstay Medical Announces US$108 Million Equity Financing Transaction
Funding to support U.S. commercial launch and global expansion Dublin – Ireland, 16 February 2021 – Mainstay Medical Holdings plc…
Read More » -
Neuro
Mainstay Medical Announces Key Strategic Hires to Drive Global Commercial Expansion
January 25, 2021 DUBLIN–(BUSINESS WIRE)–Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced recent senior leadership additions as part…
Read More » -
Neuro
Mainstay Medical Announces U.S. FDA Approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain
June 22, 2020 DUBLIN–(BUSINESS WIRE)–Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced that the U.S. Food and Drug…
Read More » -
Spine
Mainstay Medical to Showcase ReActiv8 and Key Clinical Data at the 13th German Spine Congress of the DWG
December 03, 2018 DUBLIN–(BUSINESS WIRE)–Regulatory News: Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Dublin:…
Read More » -
Spine
Mainstay Medical Announces the Completion of All Implants in the ReActiv8-B Study
July 09, 2018 DUBLIN–(BUSINESS WIRE)–Regulatory News: Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE),…
Read More » -
Spine
Mainstay Medical Announces CFO Transition
May 22, 2018 DUBLIN–(BUSINESS WIRE)– Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a…
Read More » -
Financial
Mainstay Medical Announces Half Year Financial Results
September 05, 2017 Mainstay Medical International plc (Mainstay or the Company, Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE),…
Read More » -
Neuro
Mainstay Medical Announces CEO Leadership Transition
Dublin – Ireland, 5 September 2017 – Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and ESM…
Read More » -
Financial
Mainstay Medical to seek further funding as full-year losses mount
Aug 24, 2017 – Charlie Taylor Dublin-listed Mainstay Medical, a company that is targeting chronic back pain with an implantable device, is…
Read More » -
Hospitals
Mainstay Medical’s ReActiv8-B Clinical Trial Passes Mid-point
August 03, 2017 Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange:…
Read More »